Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out
Iovance Biotherapeutics (IOVA) is rated a buy following Replimune's exit from the post-PD-1 melanoma space, giving IOVA a clearer path to market leadership. The company's lifileucel therapy shows strong efficacy in melanoma and non-small cell lung cancer (NSCLC), with commercial sales expected to reach $220M in 2025 and gross margins improving to 50%. Despite operational and adoption challenges, IOVA appears undervalued at a $1.5B market cap. Upcoming clinical and commercial catalysts could drive value if execution improves.
- ▪Replimune's lead program failure removes near-term competition for Iovance in the post-PD-1 melanoma market.
- ▪Lifileucel demonstrated best-in-class objective response rates in earlier-line melanoma and promising results in NSCLC.
- ▪Iovance expects $220M in product sales in 2025 with gross margins reaching 50%.
- ▪The company faces ongoing operational and market adoption hurdles despite its improved competitive position.
- ▪Valuation analysis suggests Iovance is undervalued at its current $1.5B market capitalization.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895107-iovance-biotherapeutics-buy-because-short-term-competitor-is-out"},"author":{"@type":"Person","name":"Biotech Play…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
